Ketamine Can Rapidly Reduce Suicidal Thoughts
By HospiMedica International staff writers Posted on 01 Jan 2018 |
Image: According to a new study, ketamine can rapidly reduce suicidal thoughts in the depressed (Photo courtesy of Erowid).
Ketamine is significantly more effective and much faster in reducing suicidal ideation in depressed patients than sedatives, according to a new study.
Researchers at Columbia University Medical Center (CUMC; New York, NY, USA) conducted a clinical trial in 80 adults with a current major depressive disorder and a Scale for Suicidal Ideation (SSI) score higher than 4 in order to test the acute effect of adjunctive, sub-anesthetic intravenous ketamine administration on clinical suicidal ideation. The patients, of whom 54% were taking antidepressant medication, were randomly assigned to receive either a ketamine or a midazolam infusion. The primary outcome measure was SSI score 24 hours after infusion.
The results revealed that within 24 hours, more patients in the ketamine group had a 50% reduction in suicidal thoughts (55%) than in the midazolam group (30%), as measured by SSI, with improvements persisting for up to six weeks. Those in the ketamine group also had greater improvement in overall mood, depression, and fatigue. Ketamine's effect on depression accounted for approximately one-third of its effect on suicidal thoughts, suggesting the treatment has a specific anti-suicidal effect. The study was published on December 5, 2017, in the American Journal of Psychiatry.
“There is a critical window in which depressed patients who are suicidal need rapid relief to prevent self-harm. Currently available antidepressants can be effective in reducing suicidal thoughts in patients with depression, but they can take weeks to have an effect,” said lead author Michael Grunebaum, MD. “Suicidal, depressed patients need treatments that are rapidly effective in reducing suicidal thoughts when they are at highest risk. Ketamine offers promise as a rapidly acting treatment for reducing suicidal thoughts in patients with depression.”
Ketamine is a rapidly acting dissociative anesthetic agent that can provide analgesia, sedation, and amnesia for rapid sequence intubation in critically ill patients. Short- and long-term effects include increased heart rate and elevated blood pressure, nausea, vomiting, numbness, depression, amnesia, hallucinations, and potentially fatal respiratory problems. Sub-anesthetic ketamine is often administered intraoperatively for postoperative analgesia due to the detached, dreamlike state it creates.
Related Links:
Columbia University Medical Center
Researchers at Columbia University Medical Center (CUMC; New York, NY, USA) conducted a clinical trial in 80 adults with a current major depressive disorder and a Scale for Suicidal Ideation (SSI) score higher than 4 in order to test the acute effect of adjunctive, sub-anesthetic intravenous ketamine administration on clinical suicidal ideation. The patients, of whom 54% were taking antidepressant medication, were randomly assigned to receive either a ketamine or a midazolam infusion. The primary outcome measure was SSI score 24 hours after infusion.
The results revealed that within 24 hours, more patients in the ketamine group had a 50% reduction in suicidal thoughts (55%) than in the midazolam group (30%), as measured by SSI, with improvements persisting for up to six weeks. Those in the ketamine group also had greater improvement in overall mood, depression, and fatigue. Ketamine's effect on depression accounted for approximately one-third of its effect on suicidal thoughts, suggesting the treatment has a specific anti-suicidal effect. The study was published on December 5, 2017, in the American Journal of Psychiatry.
“There is a critical window in which depressed patients who are suicidal need rapid relief to prevent self-harm. Currently available antidepressants can be effective in reducing suicidal thoughts in patients with depression, but they can take weeks to have an effect,” said lead author Michael Grunebaum, MD. “Suicidal, depressed patients need treatments that are rapidly effective in reducing suicidal thoughts when they are at highest risk. Ketamine offers promise as a rapidly acting treatment for reducing suicidal thoughts in patients with depression.”
Ketamine is a rapidly acting dissociative anesthetic agent that can provide analgesia, sedation, and amnesia for rapid sequence intubation in critically ill patients. Short- and long-term effects include increased heart rate and elevated blood pressure, nausea, vomiting, numbness, depression, amnesia, hallucinations, and potentially fatal respiratory problems. Sub-anesthetic ketamine is often administered intraoperatively for postoperative analgesia due to the detached, dreamlike state it creates.
Related Links:
Columbia University Medical Center
Latest Critical Care News
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia
- AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration